EMEA-000562-PIP01-09-M01 - paediatric investigation plan

semuloparin sodium

Key facts

• Active Substance:
  semuloparin sodium
• Therapeutic area:
  Haematology-Hemostaseology
• Decision number:
  P/0029/2012
• PIP number:
  EMEA-000562-PIP01-09-M01
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Thromboembolic events
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Sanofi-aventis Recherche & Développement

  France; [e-mail]; [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  30/01/2012

Decision

P/0029/2012: EMA decision of 30 January 2012 on the acceptance of a modification of an agreed paediatric investigation plan for semuloparin sodium (EMEA-000562-PIP01-09-M01)

AdoptedReference Number: EMA/931898/2011